United Therapeutics Corporation to Post Q3 2017 Earnings of $3.79 Per Share, Wedbush Forecasts (NASDAQ:UTHR)
United Therapeutics Corporation (NASDAQ:UTHR) – Research analysts at Wedbush upped their Q3 2017 earnings per share estimates for United Therapeutics Corporation in a research report issued to clients and investors on Monday. Wedbush analyst L. Moussatos now anticipates that the biotechnology company will post earnings per share of $3.79 for the quarter, up from their previous forecast of $3.77. Wedbush currently has a “Outperform” rating and a $213.00 target price on the stock. Wedbush also issued estimates for United Therapeutics Corporation’s Q4 2017 earnings at $3.51 EPS, Q1 2018 earnings at $3.61 EPS, Q2 2018 earnings at $3.15 EPS, Q3 2018 earnings at $3.31 EPS and Q4 2018 earnings at $3.28 EPS.
United Therapeutics Corporation (NASDAQ:UTHR) last announced its quarterly earnings data on Thursday, July 27th. The biotechnology company reported ($1.25) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $3.61 by $4.86. The firm had revenue of $444.60 million for the quarter, compared to analyst estimates of $391.53 million. United Therapeutics Corporation had a return on equity of 20.96% and a net margin of 24.18%. The company’s quarterly revenue was up 7.8% on a year-over-year basis. During the same quarter in the previous year, the company earned $4.42 earnings per share. COPYRIGHT VIOLATION WARNING: “United Therapeutics Corporation to Post Q3 2017 Earnings of $3.79 Per Share, Wedbush Forecasts (NASDAQ:UTHR)” was posted by American Banking News and is owned by of American Banking News. If you are accessing this piece of content on another publication, it was copied illegally and republished in violation of US and international trademark and copyright laws. The legal version of this piece of content can be viewed at https://www.americanbankingnews.com/2017/08/08/united-therapeutics-corporation-to-post-q3-2017-earnings-of-3-79-per-share-wedbush-forecasts-nasdaquthr.html.
Other analysts have also issued research reports about the company. BidaskClub lowered United Therapeutics Corporation from a “buy” rating to a “hold” rating in a research note on Wednesday, July 19th. HC Wainwright reiterated a “hold” rating and issued a $95.00 price objective on shares of United Therapeutics Corporation in a research report on Monday, April 17th. Jefferies Group LLC reiterated a “sell” rating and issued a $116.00 price objective on shares of United Therapeutics Corporation in a research report on Wednesday, April 12th. Cowen and Company reiterated a “hold” rating and issued a $121.00 price objective on shares of United Therapeutics Corporation in a research report on Wednesday, April 26th. Finally, ValuEngine downgraded United Therapeutics Corporation from a “strong-buy” rating to a “buy” rating in a report on Friday, July 28th. Six analysts have rated the stock with a sell rating, seven have assigned a hold rating and three have given a buy rating to the company. United Therapeutics Corporation has an average rating of “Hold” and an average target price of $134.50.
Shares of United Therapeutics Corporation (NASDAQ:UTHR) opened at 135.46 on Tuesday. The stock has a 50 day moving average of $130.70 and a 200-day moving average of $136.25. The firm has a market capitalization of $5.88 billion, a P/E ratio of 15.71 and a beta of 1.51. United Therapeutics Corporation has a 1-year low of $110.90 and a 1-year high of $169.89.
Hedge funds have recently modified their holdings of the company. Focused Wealth Management Inc boosted its position in United Therapeutics Corporation by 17.5% in the first quarter. Focused Wealth Management Inc now owns 940 shares of the biotechnology company’s stock worth $127,000 after buying an additional 140 shares during the last quarter. Advisory Services Network LLC purchased a new position in shares of United Therapeutics Corporation during the first quarter worth approximately $147,000. Daiwa Securities Group Inc. boosted its position in shares of United Therapeutics Corporation by 17.4% in the first quarter. Daiwa Securities Group Inc. now owns 1,350 shares of the biotechnology company’s stock worth $183,000 after buying an additional 200 shares during the last quarter. Campbell & CO Investment Adviser LLC purchased a new position in shares of United Therapeutics Corporation during the first quarter worth approximately $204,000. Finally, Eagle Global Advisors LLC purchased a new position in shares of United Therapeutics Corporation during the second quarter worth approximately $206,000.
In other United Therapeutics Corporation news, CEO Martine A. Rothblatt sold 1,259 shares of the business’s stock in a transaction dated Thursday, May 11th. The stock was sold at an average price of $122.00, for a total transaction of $153,598.00. Following the sale, the chief executive officer now owns 1,399 shares in the company, valued at approximately $170,678. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, Director Raymond Dwek sold 3,490 shares of the business’s stock in a transaction dated Friday, June 23rd. The shares were sold at an average price of $131.71, for a total value of $459,667.90. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 23,758 shares of company stock valued at $3,058,699. 7.80% of the stock is currently owned by corporate insiders.
United Therapeutics Corporation declared that its Board of Directors has approved a share repurchase plan on Thursday, April 27th that permits the company to buyback $250.00 million in shares. This buyback authorization permits the biotechnology company to buy up to 4.6% of its shares through open market purchases. Shares buyback plans are usually a sign that the company’s board of directors believes its shares are undervalued.
About United Therapeutics Corporation
United Therapeutics Corporation is a biotechnology company. The Company is focused on the development and commercialization of products for the treatment of chronic and life-threatening conditions. The Company markets and sells four commercial therapies in the United States to treat pulmonary arterial hypertension (PAH): Remodulin (treprostinil) Injection; Tyvaso (treprostinil) Inhalation Solution (Tyvaso); Orenitram (treprostinil) Extended-Release Tablets (Orenitram); and Adcirca (tadalafil) Tablets (Adcirca).
Receive News & Ratings for United Therapeutics Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for United Therapeutics Corporation and related companies with MarketBeat.com's FREE daily email newsletter.